We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Results 1 to 5 of 5
Most popular |Most recent


Generics Go Three for Three at the PTAB in Multiple Sclerosis Blockbuster Dispute

USA - September 9 2016 In the last two weeks, the PTAB has invalidated three patents covering Copaxone, a multiple sclerosis drug marketed by Teva with annual sales of over...


Early IPRs Challenging Biologic Patents: What We Know

USA - June 17 2016 Multiple IPRs challenging patents covering brand-name biologics have now been filed by biosimilar developers, for reasons we recently discussed, as...


For Biologics and Biosimilars, Don’t Forget Post-Grant Proceedings

USA - May 19 2016 Initially, biopharma represented a small percentage of post-grant proceedings; however, that percentage is increasing. In particular, generic and...


Impact of Post-Grant Proceedings on Biologics and Biosimilars

USA - April 15 2016 Biologics, primarily therapeutic antibodies and recombinant proteins, represent a growing share of the drug market and are projected to achieve...

Michael T. Siekman.


PTAB v The Untouchables: Widely Validated Biotech Patent to be Reviewed

USA - February 12 2016 The Cabilly patent family (including Cabilly I, II and III) is likely the most famous patent family in biotechnology. With claims that cover basic...